Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib Active in Iodine-Refractory Thyroid Cancer.

Cancer discovery - 1 Oct 2016

Abstract excerpt

A new study shows that the BRAF inhibitor vemurafenib may induce partial responses and stable disease in patients with papillary thyroid cancer that has become refractory to radioactive iodine. However, the drug led to a variety of serious adverse events in roughly 65% of patients, including the development of some squamous cell carcinomas.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Carcinoma, Papillary
Share to Indoles
Share to Iodine Radioisotopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Sulfonamides

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Vemurafenib

Source

Identifiers

PMID: 27554612
DOI: 10.1158/2159-8290.CD-NB2016-105

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib Active in Iodine-Refractory Thyroid Cancer.PMID 27554612Read ↗

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Semantic proximity Read ↗

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancerSemantic proximity Read ↗

Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.Semantic proximity Read ↗

Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience.Semantic proximity Read ↗

Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer.Semantic proximity Read ↗

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.Semantic proximity Read ↗

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.Semantic proximity Read ↗

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.Semantic proximity Read ↗

New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.Semantic proximity Read ↗

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.